Summit Therapeutics Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
793.1M
on 2026-06-30, from 702.0M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
S-3ASR of 2024-09-19. Not read yet. S-3ASR ↗
$380.0M
J.P. Morgan Securities, agreement of 2026-07-23. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Cash
6 quarters
$690.7M on 2026-06-30 ÷ $114.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-28 | Private placement | not read | not read | $2.00B | 8-K ↗ |
| 2025-10-21 | Private placement | 26,682,846 | $18.74 | $500.0M | 8-K ↗ |